|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.160 USD | -2.70% |
|
+4.85% | +20.00% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | 11 | +409.26% | 2 | |||||
| 1,218.72 | +10.58% | 29 | ||||||
| 252.87 | +9.33% | 23 | ||||||
| 253.83 | +10.36% | 29 | ||||||
| 358.83 | +12.63% | 18 | ||||||
| 220.86 | +25.37% | 21 | ||||||
| 154.88 | +4.08% | 21 | ||||||
| 314.41 | +4.82% | 24 | ||||||
| 352.77 | +2.33% | 30 | ||||||
| 157.57 | +26.19% | 28 | ||||||
| 29.19 | +16.38% | 27 | ||||||
| 548.69 | +17.55% | 29 | ||||||
| 63.08 | +15.32% | 25 | ||||||
| 96.7 | +33.4% | 23 | ||||||
| 20.77 | +7.91% | 19 | ||||||
| 9,973.33 | +32.59% | 15 | ||||||
| 6,086.87 | +22.35% | 15 | ||||||
| 81.14 | +64.38% | 16 | ||||||
| 49.5 | +29.65% | 19 | ||||||
| Average | 1,065.53 | +39.71% | 22 | ||||||
| Weighted average by Cap. | 716.27 | +13.42% | 25 |
- Stock Market
- Stocks
- PLX Stock
- Sector Protalix BioTherapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
